Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia [clinicaltrials:NCT00002890]
Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia [clinicaltrials:NCT00002890]
Bio2RDF identifier
NCT00002890
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00002890
identifiers.org URI
anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Monoclonal a ...... chronic myelogenous leukemia.
brief title [clinicaltrials_vocabulary:brief-title]
Monoclonal Antibody Therapy in ...... r Chronic Myelogenous Leukemia
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2001-01-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES: I. Determin ...... -18
months to complete.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-11-01T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
keyword [clinicaltrials_vocabulary:keyword]
accelerated phase chronic myelogenous leukemia
blastic phase chronic myelogenous leukemia
childhood myelodysplastic syndromes
chronic myelomonocytic leukemia
de novo myelodysplastic syndromes
previously treated myelodysplastic syndromes
recurrent adult acute myeloid leukemia
refractory anemia with excess blasts in transformation
refractory anemia with excess blasts
relapsing chronic myelogenous leukemia
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2013-06-24T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00002890
official title [clinicaltrials_vocabulary:official-title]
PHASE I DOSE-ESCALATION TRIAL ...... ADVANCED MYELOID MALIGNANCIES
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2001-01-01T00:00:00Z
secondary id [clinicaltrials_vocabulary:secondary-id]
CDR0000065213
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1996-10-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2013-06-01T00:00:00Z
identifier
clinicaltrials:NCT00002890
title
Monoclonal Antibody Therapy in ...... r Chronic Myelogenous Leukemia
@en
type
label
Monoclonal Antibody Therapy in ...... a [clinicaltrials:NCT00002890]
@en